Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Low Back Pain | 8 | 2018 | 190 | 2.94 | Why? |
| Anti-Retroviral Agents | 3 | 2019 | 1099 | 1.25 | Why? |
| Chronic Pain | 4 | 2019 | 736 | 1.23 | Why? |
| Acute Pain | 2 | 2017 | 73 | 1.22 | Why? |
| Spinal Diseases | 8 | 2021 | 238 | 1.20 | Why? |
| Analgesics, Opioid | 6 | 2019 | 1070 | 1.13 | Why? |
| Narcotic Antagonists | 2 | 2019 | 317 | 1.08 | Why? |
| Neck Pain | 2 | 2018 | 126 | 0.79 | Why? |
| United States Agency for Healthcare Research and Quality | 1 | 2018 | 6 | 0.75 | Why? |
| Masks | 8 | 2021 | 8528 | 0.75 | Why? |
| Patient Harm | 1 | 2018 | 14 | 0.73 | Why? |
| Emtricitabine | 1 | 2019 | 202 | 0.73 | Why? |
| Preventive Health Services | 3 | 2018 | 501 | 0.67 | Why? |
| Naloxone | 1 | 2017 | 153 | 0.62 | Why? |
| Glasgow Coma Scale | 1 | 2017 | 249 | 0.62 | Why? |
| Advisory Committees | 4 | 2018 | 1418 | 0.62 | Why? |
| Urinary Bladder Neoplasms | 3 | 2017 | 614 | 0.61 | Why? |
| Tenofovir | 1 | 2019 | 449 | 0.59 | Why? |
| Mass Screening | 4 | 2019 | 8005 | 0.53 | Why? |
| Buprenorphine | 1 | 2019 | 470 | 0.51 | Why? |
| Opiate Substitution Treatment | 1 | 2019 | 613 | 0.50 | Why? |
| Hepatitis B | 2 | 2017 | 888 | 0.48 | Why? |
| Lumbosacral Region | 1 | 2011 | 30 | 0.46 | Why? |
| Evidence-Based Practice | 1 | 2018 | 693 | 0.46 | Why? |
| Dental Caries | 1 | 2013 | 163 | 0.43 | Why? |
| Celiac Disease | 1 | 2017 | 471 | 0.42 | Why? |
| Emergency Medical Services | 2 | 2017 | 3557 | 0.42 | Why? |
| Physical Therapy Specialty | 1 | 2011 | 69 | 0.41 | Why? |
| Opioid-Related Disorders | 2 | 2019 | 1185 | 0.40 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2019 | 1138 | 0.40 | Why? |
| Neoplasm Recurrence, Local | 1 | 2016 | 1063 | 0.39 | Why? |
| HIV Infections | 3 | 2019 | 11620 | 0.38 | Why? |
| Guidelines as Topic | 2 | 2018 | 2844 | 0.35 | Why? |
| Global Burden of Disease | 4 | 2018 | 531 | 0.34 | Why? |
| Pain | 2 | 2018 | 1084 | 0.33 | Why? |
| Coronavirus Infections | 12 | 2021 | 253789 | 0.32 | Why? |
| Radiculopathy | 2 | 2017 | 79 | 0.32 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.32 | Why? |
| BCG Vaccine | 1 | 2016 | 1137 | 0.31 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.31 | Why? |
| Neurosurgical Procedures | 1 | 2017 | 1738 | 0.28 | Why? |
| Health Personnel | 9 | 2021 | 29646 | 0.28 | Why? |
| Pain Management | 4 | 2018 | 854 | 0.28 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.27 | Why? |
| CD4 Lymphocyte Count | 2 | 2019 | 1517 | 0.27 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.26 | Why? |
| Back Pain | 3 | 2018 | 115 | 0.25 | Why? |
| Risk Factors | 10 | 2021 | 71621 | 0.24 | Why? |
| Humans | 57 | 2021 | 930598 | 0.24 | Why? |
| HIV | 2 | 2019 | 1116 | 0.23 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2019 | 5164 | 0.23 | Why? |
| Antineoplastic Agents | 2 | 2017 | 3550 | 0.22 | Why? |
| Cystectomy | 3 | 2017 | 218 | 0.22 | Why? |
| Intubation, Intratracheal | 1 | 2017 | 3962 | 0.21 | Why? |
| Practice Guidelines as Topic | 8 | 2021 | 15421 | 0.20 | Why? |
| Delphi Technique | 6 | 2018 | 1257 | 0.20 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.19 | Why? |
| Risk Evaluation and Mitigation | 1 | 2018 | 33 | 0.18 | Why? |
| Contraceptives, Oral, Combined | 1 | 2018 | 20 | 0.18 | Why? |
| Fractures, Compression | 1 | 2017 | 33 | 0.17 | Why? |
| United States Public Health Service | 1 | 2018 | 50 | 0.17 | Why? |
| Neoplasm Invasiveness | 2 | 2017 | 582 | 0.17 | Why? |
| Risk | 3 | 2019 | 5288 | 0.17 | Why? |
| Administration, Intravesical | 1 | 2016 | 94 | 0.17 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.17 | Why? |
| Transglutaminases | 1 | 2017 | 77 | 0.16 | Why? |
| Neuromuscular Agents | 1 | 2017 | 87 | 0.16 | Why? |
| Mind-Body Therapies | 1 | 2017 | 71 | 0.16 | Why? |
| Prenatal Diagnosis | 1 | 2019 | 345 | 0.16 | Why? |
| GTP-Binding Proteins | 1 | 2017 | 132 | 0.16 | Why? |
| Spinal Fractures | 1 | 2017 | 124 | 0.15 | Why? |
| Injury Severity Score | 1 | 2017 | 287 | 0.15 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.15 | Why? |
| Analgesics, Non-Narcotic | 1 | 2017 | 164 | 0.15 | Why? |
| Urinary Bladder | 1 | 2016 | 170 | 0.15 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.15 | Why? |
| Fetus | 1 | 2019 | 484 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Benzodiazepines | 1 | 2017 | 163 | 0.15 | Why? |
| Immunoenzyme Techniques | 1 | 2017 | 448 | 0.15 | Why? |
| Diet, Gluten-Free | 1 | 2017 | 185 | 0.15 | Why? |
| Osteoporotic Fractures | 1 | 2017 | 175 | 0.14 | Why? |
| Evidence-Based Medicine | 5 | 2021 | 3228 | 0.14 | Why? |
| Injections, Intramuscular | 1 | 2017 | 800 | 0.14 | Why? |
| Disability Evaluation | 1 | 2018 | 671 | 0.14 | Why? |
| Magnetic Resonance Imaging | 1 | 2011 | 6551 | 0.14 | Why? |
| Xylitol | 1 | 2013 | 10 | 0.13 | Why? |
| Fluorides | 1 | 2013 | 16 | 0.13 | Why? |
| Health Education, Dental | 1 | 2013 | 14 | 0.13 | Why? |
| Acetaminophen | 1 | 2017 | 326 | 0.13 | Why? |
| Dental Caries Susceptibility | 1 | 2013 | 43 | 0.13 | Why? |
| United States | 9 | 2019 | 46150 | 0.13 | Why? |
| Patient Education as Topic | 3 | 2018 | 1476 | 0.13 | Why? |
| Chemotherapy, Adjuvant | 1 | 2016 | 606 | 0.13 | Why? |
| Urinary Tract Infections | 1 | 2019 | 534 | 0.13 | Why? |
| Pregnancy Complications, Infectious | 1 | 2019 | 11559 | 0.13 | Why? |
| Administration, Intranasal | 1 | 2017 | 1132 | 0.13 | Why? |
| Delivery of Health Care | 4 | 2021 | 15909 | 0.12 | Why? |
| Acupuncture Therapy | 1 | 2017 | 234 | 0.12 | Why? |
| Self Care | 2 | 2018 | 918 | 0.12 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.12 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.12 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.12 | Why? |
| Radiography | 1 | 2020 | 1576 | 0.12 | Why? |
| Health Facilities | 1 | 2020 | 1230 | 0.12 | Why? |
| Developing Countries | 5 | 2018 | 4283 | 0.12 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.11 | Why? |
| Antidepressive Agents | 1 | 2017 | 509 | 0.11 | Why? |
| Anticonvulsants | 1 | 2017 | 634 | 0.11 | Why? |
| Critical Pathways | 2 | 2018 | 1587 | 0.11 | Why? |
| Drug Overdose | 1 | 2017 | 583 | 0.11 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.10 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.10 | Why? |
| Patient Compliance | 1 | 2020 | 1468 | 0.10 | Why? |
| Equipment Safety | 1 | 2011 | 167 | 0.10 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.10 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.10 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.10 | Why? |
| Psychotherapy | 1 | 2017 | 747 | 0.09 | Why? |
| Child Health | 1 | 2018 | 940 | 0.09 | Why? |
| Physical Therapy Modalities | 1 | 2017 | 1090 | 0.09 | Why? |
| Sensitivity and Specificity | 3 | 2017 | 22971 | 0.09 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.08 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.08 | Why? |
| Global Health | 3 | 2021 | 13911 | 0.08 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.08 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.08 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.07 | Why? |
| Immunoglobulin A | 1 | 2017 | 3567 | 0.07 | Why? |
| Adolescent | 4 | 2019 | 86841 | 0.07 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| Ultrasonography | 1 | 2020 | 4409 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.07 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2018 | 2739 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2019 | 5883 | 0.06 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.05 | Why? |
| Medical Oncology | 1 | 2017 | 3826 | 0.05 | Why? |
| Pain Measurement | 2 | 2014 | 533 | 0.05 | Why? |
| Child | 3 | 2019 | 70012 | 0.05 | Why? |
| Patient Care | 1 | 2011 | 1664 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Chronic Disease | 2 | 2014 | 5139 | 0.05 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.05 | Why? |
| Parents | 1 | 2013 | 2758 | 0.05 | Why? |
| Female | 7 | 2019 | 380317 | 0.05 | Why? |
| Ethinyl Estradiol | 1 | 2018 | 3 | 0.05 | Why? |
| Adult | 4 | 2019 | 244371 | 0.05 | Why? |
| Orthotic Devices | 1 | 2017 | 9 | 0.05 | Why? |
| Progestins | 1 | 2018 | 43 | 0.05 | Why? |
| Viral Load | 1 | 2019 | 15850 | 0.04 | Why? |
| Treatment Outcome | 2 | 2016 | 51732 | 0.04 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.04 | Why? |
| Clinical Competence | 1 | 2013 | 3263 | 0.04 | Why? |
| Urinary Diversion | 1 | 2017 | 26 | 0.04 | Why? |
| Disease Progression | 1 | 2016 | 13580 | 0.04 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.04 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2016 | 7330 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2019 | 10083 | 0.04 | Why? |
| Pelvis | 1 | 2017 | 125 | 0.04 | Why? |
| Muscles | 1 | 2017 | 152 | 0.04 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.04 | Why? |
| Male | 5 | 2019 | 367725 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Medical History Taking | 1 | 2018 | 350 | 0.04 | Why? |
| Spine | 1 | 2018 | 292 | 0.04 | Why? |
| Watchful Waiting | 1 | 2017 | 276 | 0.04 | Why? |
| Lymph Node Excision | 1 | 2017 | 362 | 0.04 | Why? |
| Primary Health Care | 1 | 2013 | 4839 | 0.04 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.03 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.03 | Why? |
| Professional-Patient Relations | 1 | 2018 | 426 | 0.03 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.03 | Why? |
| Job Satisfaction | 1 | 2018 | 647 | 0.03 | Why? |
| Public Health | 1 | 2018 | 16359 | 0.03 | Why? |
| Physical Examination | 1 | 2018 | 755 | 0.03 | Why? |
| Educational Status | 1 | 2018 | 1451 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Child Health Services | 1 | 2018 | 520 | 0.03 | Why? |
| Algorithms | 2 | 2019 | 7346 | 0.03 | Why? |
| Policy Making | 1 | 2018 | 829 | 0.03 | Why? |
| Government Regulation | 1 | 2018 | 842 | 0.03 | Why? |
| Databases, Factual | 2 | 2017 | 6248 | 0.03 | Why? |
| Infant | 1 | 2013 | 30274 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2017 | 1999 | 0.02 | Why? |
| Professional Competence | 1 | 2013 | 246 | 0.02 | Why? |
| Diagnostic Imaging | 1 | 2018 | 1044 | 0.02 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Exercise Therapy | 1 | 2017 | 976 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Datasets as Topic | 1 | 2014 | 1404 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2017 | 2149 | 0.02 | Why? |
| Orthopedic Procedures | 1 | 2018 | 1231 | 0.02 | Why? |
| Health Education | 1 | 2018 | 1539 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Social Determinants of Health | 1 | 2018 | 1757 | 0.02 | Why? |
| Cross-Sectional Studies | 1 | 2013 | 53120 | 0.02 | Why? |
| Occupational Stress | 1 | 2018 | 2044 | 0.02 | Why? |
| Occupational Diseases | 1 | 2018 | 2787 | 0.01 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.01 | Why? |
| Communication | 1 | 2018 | 5206 | 0.01 | Why? |
| Curriculum | 1 | 2013 | 3083 | 0.01 | Why? |
| Triage | 1 | 2018 | 7151 | 0.01 | Why? |
| Consensus | 1 | 2013 | 6345 | 0.01 | Why? |
| Education, Medical | 1 | 2013 | 2461 | 0.01 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Biomedical Research | 1 | 2014 | 5270 | 0.01 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.01 | Why? |
Chou's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(218)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(77)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_